MX2022008487A - Degradadores de smarca2-vhl. - Google Patents

Degradadores de smarca2-vhl.

Info

Publication number
MX2022008487A
MX2022008487A MX2022008487A MX2022008487A MX2022008487A MX 2022008487 A MX2022008487 A MX 2022008487A MX 2022008487 A MX2022008487 A MX 2022008487A MX 2022008487 A MX2022008487 A MX 2022008487A MX 2022008487 A MX2022008487 A MX 2022008487A
Authority
MX
Mexico
Prior art keywords
smarca2
degraders
vhl
compound
formula
Prior art date
Application number
MX2022008487A
Other languages
English (en)
Spanish (es)
Inventor
Victor J Cee
Ning Chen
Ryan Paul Wurz
Xiaofen Li
Abhisek Banerjee
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022008487A publication Critical patent/MX2022008487A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022008487A 2020-01-10 2021-01-08 Degradadores de smarca2-vhl. MX2022008487A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062959502P 2020-01-10 2020-01-10
PCT/US2021/012683 WO2021142247A1 (en) 2020-01-10 2021-01-08 Smarca2-vhl degraders

Publications (1)

Publication Number Publication Date
MX2022008487A true MX2022008487A (es) 2022-08-02

Family

ID=74495106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008487A MX2022008487A (es) 2020-01-10 2021-01-08 Degradadores de smarca2-vhl.

Country Status (7)

Country Link
US (1) US20230091042A1 (https=)
EP (1) EP4087658A1 (https=)
JP (1) JP7706456B2 (https=)
AU (1) AU2021205326A1 (https=)
CA (1) CA3167166A1 (https=)
MX (1) MX2022008487A (https=)
WO (1) WO2021142247A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
WO2022029617A1 (en) * 2020-08-04 2022-02-10 Aurigene Discovery Technologies Limited 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
EP4259144A4 (en) * 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
US11993599B2 (en) 2021-08-09 2024-05-28 Genentech, Inc. Therapeutic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
US20190300521A1 (en) * 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US12371426B2 (en) * 2018-04-26 2025-07-29 Aurigene Discovery Technologies Limited Pyridazine derivatives as SMARCA2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)

Also Published As

Publication number Publication date
US20230091042A1 (en) 2023-03-23
EP4087658A1 (en) 2022-11-16
AU2021205326A1 (en) 2022-07-21
WO2021142247A1 (en) 2021-07-15
JP2023510746A (ja) 2023-03-15
JP7706456B2 (ja) 2025-07-11
CA3167166A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MX2022008487A (es) Degradadores de smarca2-vhl.
ZA202209563B (en) Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
ZA202206923B (en) New methylquinazolinone derivatives
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MY209614A (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
MX2024000299A (es) Compuestos antivirales.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
TN2016000489A1 (en) Carboxamide derivatives.
MX2021007247A (es) Derivados de rapamicina.
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12021552953A1 (en) Tricyclic compounds
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
CR20230125A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
ZA202204251B (en) Compounds and compositions for the treatment of parasitic diseases